🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Blood mutations in >200,000 people UK Biobank tell us more about risk of multiple diseases and aging process nature.com/articles/s4158… Nature Genetics

As members of the Blood Cancer Alliance we’re asking the next government to: 🕑Ensure people with blood cancer are diagnosed earlier 💊Deliver better experiences and outcomes from treatment 🧬Help more people access clinical trials and reduce inequalities in access to research

1/x *** New Research ***. 😀What can be done to protect immunocompromised patients? New press release from AstraZeneca. astrazeneca.com/media-centre/p…, and it's about a therapy called Sipavibart, the successor to Evusheld.

Watching CPFC TAKE Aston Villa apart. 🦅🦅🦅🦅🦅

For readers interested in bispecific antibodies for cancer therapy, here's a comprehensive recent review bit.ly/3T7gZkH rdcu.be/dIULN

This is a very provocative study by Harsh Parmar MD et al Use of lenalidomide maintenance in a large real-world cohort (971 no maint, 957 with maint) was not associated with improved overall survival in patients with myeloma. The question is in what direction confounding occurred

Tears of Joy for England and Harry. Semis here we come #euros24

The meta-analysis of real-world studies of axi-cel versus tisa-cel in relapsed/refractory DLBCL finds that axi-cel significantly improves responses and progression-free survival, while tisa-cel significantly reduces higher-grade CRS and neurotoxicity. ow.ly/Q1sx50SNJ6z

Excellent panel discussion on the hard-to-treat complications of allogeneic hematopoietic cell transplantation and CAR T-cell therapy at the 2024 IACH by Mohamad Mohty @SelimCorbaciog1 Razan Mohty Antonio Pagliuca iman aboudalle in #Paris

#IMS24 marivi mateos reveals what we’ve all heard in passing - an OS benefit with cilta-cel in CARTITUDE-4! BCMA CAR-T now officially can improve overall survival vs DPd/PVd in myeloma #MMsm 🎉 Improvement in PFS, OS, *and* in PROs - the trifecta we’ve all been looking for!

We are deeply disappointed by the suspension of the health technology appraisal for Sipavibart, a preventative COVID-19 treatment. Anthony Nolan Leukaemia UK Myeloma UK

Source: JP Weiland

Another study confirming that SARS-CoV-2 can be PRESENT both FREELY CIRCULATING in the BLOODSTREAM as well as infecting the cells that line the blood vessels ! 💥💥💥 This indicates viral dissemination, allowing the virus to infect multiple organs ! virologyj.biomedcentral.com/articles/10.11…

In a phase 1 trial, patients with T-ALL receiving allogeneic #CD5-targeted #CARTtherapy, show an encouraging clinical response rate, with some severe adverse events that require attention and effective management. #AllogeneicCART #Leukemia nature.com/articles/s4159…

Danielle Beckman The study aimed to investigate the long-term cognitive deficits in patients who were hospitalized with COVID-19, including those with and without acute neurological complications. The researchers wanted to understand the relationship between cognitive impairment, brain injury

We’re delighted to hear that exa-cel has been approved by NICE to treat sickle cell disorder! This innovative gene therapy is the first of its kind, offering a potential cure to people without a stem cell donor.

“I never imagined how incredibly fulfilling the experience would be... My decision to join the register and follow through with the donation had the potential to change someone’s life — something I’ll never take for granted.” - Chiara, who donated her stem cells via PBSC

Together with our supporter Jason we're calling for CAR-T cell treatments to be made available for #myeloma patients on the NHS. The ability to pay should never be a barrier to accessing life-changing treatments. Read more: bbc.co.uk/news/articles/…

Other than the brain, our immune system is the most complex part of the human body. For the first time, sequencing receptors of B and T cells, along with generative A.I., enabled diagnosis of medical conditions such as lupus and Type 1 diabetes. That's just for starters.

The most impressive myeloma abstract at #ASCO25 Outstanding longterm efficacy with cilta-cel CAR-T. 5 year survival rate 50% 5 year PFS rate of 33% Astounding given multi-drug relapsed refractory setting. Plasma Cell Pete Noopur Raje Tom Martin Yi Lin Deepu Madduri